CMS May Review Rx Prices In Medicare Bids; “Non-Interference” Has Limits
Executive Summary
The Medicare Part D implementing regs would allow CMS to ask drug plan sponsors to provide detailed descriptions of manufacturer-level prices and rebates in cases where bids appear "unusually" high or low